Corbus Pharmaceuticals Files 8-K
Ticker: CRBP · Form: 8-K · Filed: Dec 3, 2024 · CIK: 1595097
Sentiment: neutral
Topics: 8-K, corporate-events, filing
TL;DR
Corbus Pharma dropped an 8-K on 12/3 - check for Reg FD, other events, and financials.
AI Summary
Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on December 3, 2024, to report on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company, incorporated in Delaware, is located at 500 River Ridge Drive, Norwood, Massachusetts.
Why It Matters
This 8-K filing provides updates on Corbus Pharmaceuticals' corporate activities, including regulatory disclosures and financial information, which are important for investors to monitor.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting various corporate events and financial information, not indicating any immediate significant risks.
Key Numbers
- 001-37348 — SEC File Number (Identifies the company's filing with the SEC.)
- 46-4348039 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Corbus Pharmaceuticals Holdings, Inc. (company) — Registrant
- December 03, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 500 River Ridge Drive Norwood, Massachusetts 02062 (address) — Principal Executive Offices
- SAV Acquisition Corp (company) — Former Company Name
FAQ
What specific events are being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text snippet.
What are the 'Other Events' being reported by Corbus Pharmaceuticals?
The filing lists 'Other Events' as an item, but the specific nature of these events is not detailed in the provided text.
What financial statements and exhibits are included with this 8-K filing?
The filing states that 'Financial Statements and Exhibits' are included, but the content of these documents is not specified in the provided text.
When was Corbus Pharmaceuticals Holdings, Inc. incorporated?
Corbus Pharmaceuticals Holdings, Inc. was incorporated in Delaware.
What was the former name of Corbus Pharmaceuticals Holdings, Inc.?
The former name of Corbus Pharmaceuticals Holdings, Inc. was SAV Acquisition Corp.
Filing Stats: 684 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2024-12-03 08:00:09
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CRBP The Nasdaq Capital M
Filing Documents
- crbp-20241203.htm (8-K) — 46KB
- crbp-ex99_1.htm (EX-99.1) — 15KB
- 0000950170-24-132458.txt ( ) — 185KB
- crbp-20241203.xsd (EX-101.SCH) — 31KB
- crbp-20241203_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 3, 2024, Corbus Pharmaceuticals Holdings, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission (the "SEC"), and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
01 Other Events
Item 8.01 Other Events. On December 3, 2024, the Company announced that the FDA has granted Fast Track designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer. CRB-701 is a next-generation antibody drug conjugate targeting Nectin-4 that contains a site-specific, cleavable linker and a precise drug antibody ratio of 2 using MMAE as the payload. The Company recently completed enrollment of the dose escalation part of its bridging Phase 1 clinical trial of CRB-701 that is being conducted in the U.S. and Europe. The three-part Phase 1 trial is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in patients with advanced solid tumors known to be associated with high Nectin-4 expression. The Company expects to report the first data from the dose escalation clinical study in the first quarter of 2025.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Corbus Pharmaceuticals Holdings, Inc. dated December 3, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Corbus Pharmaceuticals Holdings, Inc. Date: December 3, 2024 By: /s/ Yuval Cohen Name: Yuval Cohen Title: Chief Executive Officer